Pharmaceutical Market Europe • May 2024 • 46
APPOINTMENTS
Gilead Sciences
Peter Wickersham
Gilead Sciences has appointed Peter Wickersham as vice-president and general manager for the UK and Ireland. Wickersham, who has more than 25 years of experience in the pharmaceutical industry, brings a wealth of commercial expertise and strategic acumen to his new role. He recently led Gilead’s liver disease and COVID-19 business unit in the US and, prior to this, was vice-president of US managed markets. Before joining Gilead, Wickersham was president, government programmes division at Express Scripts and executive pharmacy officer and vice president, health services operations at Blue Cross and Blue Shield of Minnesota. He has also held senior positions at Merck & Co and Prime Therapeutics. In his new role, he will be responsible for leading Gilead’s commercial organisation in the affiliate.
George Medicines
Mark Mallon
George Medicines has appointed Mark Mallon as CEO. Mallon brings extensive industry experience to the role and recently served as CEO for NeoGenomics Laboratories and Ironwood Pharmaceuticals. Mallon also spent over 24 years at AstraZeneca in various roles, including Executive VP of International and Executive VP of Product and Portfolio Strategy.
LifeArc
Sam Barrell
LifeArc has appointed Sam Barrell as CEO. Barrell joins the organisation from the Francis Crick Institute, where she has most recently been serving as deputy CEO. She was also previously non-executive director of York Health Economics Consortium and has held a number of senior leadership positions in the NHS.
Asklepios BioPharmaceutical
Mansuo Shannon
Asklepios BioPharmaceutical has appointed Mansuo Shannon as chief scientific officer. Shannon has over 16 years of industry experience and joins the company from Prevail Therapeutics, where she also served as chief scientific officer. Prior to this, Shannon served in a number of roles at Eli Lilly, including as research fellow and senior director.
UCB
Fiona du Monceau
UCB has appointed Fiona du Monceau as executive VP patient evidence. Du Monceau holds significant industry experience and has held a number of roles at UCB, including head of EU bone division and vice chairman of the board. She was also previously ExeVir Bio’s chief operating officer and worked in various positions at Eli Lilly.
Pfizer
Andrew Baum
Pfizer has appointed Andrew Baum as chief strategy and innovation officer, executive vice president. Baum joins the company from Citi, where he served as head of global healthcare, managing director equity research. Prior to this, Baum covered European pharmaceuticals at Morgan Stanley and was a practising physician earlier in his career.
Barinthus Biotherapeutics
Leon Hooftman
Barinthus Biotherapeutics has appointed Leon Hooftman as chief medical officer. Hooftman brings significant drug development experience to the role and joins Barinthus from ISA Pharmaceuticals, where he has been serving as chief medical officer. He has held the same position at several biotech companies and held senior management positions at Roche and UCB Celltech.
Sandoz
Mathai Mammen
Sandoz has appointed Mathai Mammen to its board of directors. Mammen brings extensive experience to the role and is currently chief executive officer and chairman at FogPharma. He previously served as executive vice president, pharmaceuticals, research and development at Johnson & Johnson, and also held senior R&D roles at Merck, Innoviva and Theravance.
Cresset
Mutlu Dogruel
Cresset has appointed Mutlu Dogruel as vice president for AI solutions. Dogruel joins the company from Microsoft, where he held positions including pharma and GenAI lead architect and senior cloud solution architect in data and AI. He has also held roles at Eagle Genomics, HP Autonomy and the Wellcome Sanger Institute.
Pharmaceutical Market Europe (PME)
Pharmaceutical industry news, articles, jobs, reports, advice and services